tazemetostat (Taxverik)
Jump to navigation
Jump to search
Indications
* 13% objective response rate in two small cohorts of patients with advanced epithelioid sarcoma
Dosage
- 800 mg BID with or without food
Tabs: 200 mg
Pharmacokinetics
- mebolized by CYP3A
- 88% bound to plasma proteins
- volume of distribution 1230 L
- terminal elimation 1/2life is 3.1 hours
- inactive metabolites excreted in urine 15% & feces 79%
Adverse effects
- pain: musculoskeletal pain & abdominal pain
- nausea, vomiting decreased appetite, constipation
- fatigue
Mechanism of action
- methyltransferase inhibitor
Notes
- doxorubicin with 24% response rate in epithelioid sarcoma (FDA approval ~1974)
More general terms
References
- ↑ Bankhead C Thumbs Up From FDA Panel for Sarcoma Drug. Unanimous vote to approve tazemetostat in epithelioid sarcoma MedPage Today. Dec 18, 2019
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION TAZVERIK (tazemetostat) tablets, for oral use https://www.tazverik.com/Content/pdf/prescribing-information.pdf